Patents by Inventor Catherine Druez

Catherine Druez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for producing antibodies which specifically bind to interleukin-9 receptor
    Patent number: 5962269
    Abstract: The invention describes nucleic acid sequences which code for the interleukin 9 receptor (IL9-R) molecule. These sequences may be used as probes to identify cells expressing the molecule, and as agents to transfect recipient cells.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: October 5, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Jean-Christophe Renauld, Catherine Druez, Jacques Van Snick
  • Nucleic acid sequences coding for or complementary to nucleic acid sequences coding for interleukin 9 receptor
    Patent number: 5789237
    Abstract: The invention describes nucleic acid sequences which code for the interleukin 9 receptor (IL9-R) molecule. These sequences may be used as probes to identify cells expressing the molecule, and as agents to transfect recipient cells.
    Type: Grant
    Filed: December 8, 1993
    Date of Patent: August 4, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Jean-Christophe Renauld, Catherine Druez, Jacques Van Snick
  • Method for inhibiting production of IgE by using IL-9 inhibitors
    Patent number: 5246701
    Abstract: A method for inhibiting production of IgE, and a method for enhancing production of IgG are taught. The methods are linked to the role of interleukin 9 in antibody production. Specifically, production of IgG is potentiated by administering either to a subject or a cell culture a combination of interleukin 4 and interleukin 9. Production of IgE is inhibited by administering an amount of an interleukin 9 inhibitor to a subject.
    Type: Grant
    Filed: December 13, 1991
    Date of Patent: September 21, 1993
    Assignees: Ludwig Institute for Cancer Research, Department d'Immunologie Institut Henri Beaufour
    Inventors: Bernard Dugas, Catherine Druez, Pierre Braquet, Jean M. Mencia-Huerta, Catherine Uyttenhove, Jean-Christophe Renauld, Jacques Van Snick
  • Uses of substantially pure interleukin-9 receptor
    Patent number: 5180678
    Abstract: The invention relates to substantially pure interleukin 9 receptor molecules and the use thereof. The uses include use as an interleukin-9 inhibitor, as a diagnostic agent for determining interleukin-9, and as a screening agent for pharmaceuticals. The interleukin-9 receptor is characterized as a glycoprotein of about 64 kilodaltons which, upon digestion with N-glycosidase F, yields a peptide of about 54 kilodaltons.
    Type: Grant
    Filed: February 6, 1992
    Date of Patent: January 19, 1993
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Catherine Druez, Pierre Coulie, Catherine Uyttenhove, Jacques Van Snick
  • Method for inhibiting production of IGE and method for enhancing production of IGG using interleukin 9 and inhibitors thereof
    Patent number: 5132109
    Abstract: A method for inhibiting production of IgE, and a method for enhancing production of IgG are taught. The methods are linked to the role of interleukin 9 in antibody production. Specifically, production of IgG is potentiated by administering either to a subject or a cell culture a combination of interleukin 4 and interleukin 9. Production of IgE is inhibited by administering an amount of an interleukin 9 inhibitor to a subject.
    Type: Grant
    Filed: October 5, 1990
    Date of Patent: July 21, 1992
    Assignees: Ludwig Institute for Cancer Research, Departemente d'Immunologie Institut Henri Beaufour
    Inventors: Bernard Dugas, Catherine Druez, Pierre Braquet, Jean M. Mencia-Huerta, Catherine Uyttenhove, Jean-Christophe Renauld, Jacques Van Snick
  • Substantially pure interleukin-9 receptor and uses thereof
    Patent number: 5116951
    Abstract: The invention relates to substantially pure interleukin 9 receptor molecules and the use thereof. The uses include use as an interleukin-9 inhibitor, as a diagnostic agent for determining interleukin-9, and as a screening agent for pharmaceuticals. The interleukin-9 receptor is characterized as a glycoprotein of about 94 kilodaltons which, upon digestion with N-glycosidase F, yields a peptide of about 54 kilodaltons.
    Type: Grant
    Filed: September 19, 1990
    Date of Patent: May 26, 1992
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Catherine Druez, Pierre Coulie, Catherine Uyttenhove, Jacques Van Snick